PAC0013PR: Pancreatic Ductal Adenocarcinoma

TRACE-PDTX platform


Patient
Sex Female
Age at Time of Collection 85
Race / Ethnicity / Not Specified
Patient Tumor
Histology Pancreatic Ductal Adenocarcinoma
Primary Tissue pancreas
Collection Site pancreas
Tumor Type Primary
Grade Not specified
Stage cT3N0M0 ( Classification: TNM staging system)
PDX model Engraftment
Host Strain Name Site Type Material Material Status Passage
NMRI nude interscapular fat pad heterotopic tissue biopsy fresh 0, 1, 2, 3, 4
Model Quality Control
Technique Description Passage
Histology high concordance between xenograft and patient tumour 0,1,2,3,4
Fingerprinting high concordance between xenograft and patient tumour 0,1,2,3,4
Collection (Current Model)
Age 85
Diagnosis Pancreatic Ductal Adenocarcinoma
Type Primary
PDX Mouse PAC0013PR
Collection Site pancreas
Sex Female
Race / Ethnicity Not specified / Not Specified
Date Regimen Started Regimen Dose Best Response Duration (Months)
Aug 07 Cyclophosphamide and vincristine and prednisone and Doxorubicin cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1,4 mg/m2 on day 1, and prednisone 40 mg/m2 on day 1 to 5. Doxorubicin and cyclophosphamide reduced to 50% and repeated evey 3 weeks / cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1,4 mg/m2 on day 1, and prednisone 40 mg/m2 on day 1 to 5. Doxorubicin and cyclophosphamide reduced to 50% and repeated evey 3 weeks / cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1,4 mg/m2 on day 1, and prednisone 40 mg/m2 on day 1 to 5. Doxorubicin and cyclophosphamide reduced to 50% and repeated evey 3 weeks / cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1,4 mg/m2 on day 1, and prednisone 40 mg/m2 on day 1 to 5. Doxorubicin and cyclophosphamide reduced to 50% and repeated evey 3 weeks Complete Response 1.0 / 1.0 / 1.0 / 1.0
May 08 prednisone and Procarbazine and vincristine and chlorambucil Vincristine 1,4 mg/m2 on day 1 and 8, chlorambucil, 4 mg/m2, procarbazine 70 mg/m2 and prednisone 25 mg/m2 on day 1 to 14. All repeated evey 4 weeks / Vincristine 1,4 mg/m2 on day 1 and 8, chlorambucil, 4 mg/m2, procarbazine 70 mg/m2 and prednisone 25 mg/m2 on day 1 to 14. All repeated evey 4 weeks / Vincristine 1,4 mg/m2 on day 1 and 8, chlorambucil, 4 mg/m2, procarbazine 70 mg/m2 and prednisone 25 mg/m2 on day 1 to 14. All repeated evey 4 weeks / Vincristine 1,4 mg/m2 on day 1 and 8, chlorambucil, 4 mg/m2, procarbazine 70 mg/m2 and prednisone 25 mg/m2 on day 1 to 14. All repeated evey 4 weeks Complete Response 4.0 / 4.0 / 4.0 / 4.0
May 07 prednisone and vincristine and Cyclophosphamide and Doxorubicin cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1-2 mg/m2 on day 1,and prednisone 40 mg/m2 on day 1 to 5. All reduced to 80% and repeated evey 3 weeks / cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1-2 mg/m2 on day 1,and prednisone 40 mg/m2 on day 1 to 5. All reduced to 80% and repeated evey 3 weeks / cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1-2 mg/m2 on day 1,and prednisone 40 mg/m2 on day 1 to 5. All reduced to 80% and repeated evey 3 weeks / cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1-2 mg/m2 on day 1,and prednisone 40 mg/m2 on day 1 to 5. All reduced to 80% and repeated evey 3 weeks Complete Response 3.0 / 3.0 / 3.0 / 3.0

Sample ID:     Histology:     Tumor Type: Engrafted Tumor     Passage:     Platform: